Daiichi Sankyo reveals 4 patient deaths in halted nimotuzumab trial
Tokyo-based Daiichi Sankyo Co. Ltd. discontinued a phase III trial for nimotuzumab on the recommendation of an independent data monitoring committee after four treatment-related deaths were observed, all in the nimotuzumab arm.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter